Royal Bank of Canada
CATX icon

Royal Bank of Canada’s Perspective Therapeutics CATX Stock Holding History

Royal Bank of Canada’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19K Sell
4,500
-1,439
-24% -$6.08K ﹤0.01% 5914
2025
Q4 		$16K Sell
5,939
-9,858
-62% -$28.1K ﹤0.01% 6164
2025
Q3 		$54K Buy
15,797
+5,622
+55% +$20.5K ﹤0.01% 5786
2025
Q2 		$35K Buy
10,175
+6,760
+198% +$17.8K ﹤0.01% 6065
2025
Q1 		$7K Sell
3,415
-1,985
-37% -$5.96K ﹤0.01% 6247
2024
Q4 		$17K Sell
5,400
-1,409
-21% -$11.5K ﹤0.01% 6167
2024
Q3 		$91K Buy
6,809
+2,380
+54% +$31.7K ﹤0.01% 5405
2024
Q2 		$44K Buy
4,429
+4,369
+7,282% +$63.2K ﹤0.01% 5713
2024
Q1 		$1K Buy
60
+37
+161% +$315 ﹤0.01% 6766
2023
Q4 		$0 Sell
23
-200
-90% -$563 ﹤0.01% 7147
2023
Q3 		$1K Buy
223
+197
+758% +$919 ﹤0.01% 6871
2023
Q2 		$0 Sell
26
-2,496
-99% -$15.2K ﹤0.01% 7281
2023
Q1 		$16K Buy
2,522
+4
+0.2% +$16 ﹤0.01% 6105
2022
Q4 		$6K Buy
2,518
+4
+0.2% +$13 ﹤0.01% 6681
2022
Q3 		$6K Buy
2,514
+14
+0.6% +$48 ﹤0.01% 6645
2022
Q2 		$8K Sell
2,500
-13
-0.5% -$40 ﹤0.01% 6453
2022
Q1 		$9K Sell
2,513
-56
-2% -$204 ﹤0.01% 6986
2021
Q4 		$10K Sell
2,569
-101
-4% -$539 ﹤0.01% 7039
2021
Q3 		$17K Sell
2,670
-830
-24% -$5.66K ﹤0.01% 6764
2021
Q2 		$28K Buy
3,500
+2,100
+150% +$18.4K ﹤0.01% 6380
2021
Q1 		$15K Sell
1,400
-656
-32% -$9.91K ﹤0.01% 6594
2020
Q4 		$9K Hold
2,056
– – ﹤0.01% 6413
2020
Q3 		$12K Buy
2,056
+7
+0.3% +$46 ﹤0.01% 5865
2020
Q2 		$11K Sell
2,049
-177
-8% -$1.14K ﹤0.01% 5796
2020
Q1 		$12K Hold
2,226
– – ﹤0.01% 5753
2019
Q4 		$14K Buy
2,226
+126
+6% +$553 ﹤0.01% 6008
2019
Q3 		$7K Hold
2,100
– – ﹤0.01% 5885
2019
Q2 		$9K Hold
2,100
– – ﹤0.01% 6051
2019
Q1 		$8K Hold
2,100
– – ﹤0.01% 6080
2018
Q4 		$6K Hold
2,100
– – ﹤0.01% 6093
2018
Q3 		$11K Hold
2,100
– – ﹤0.01% 5937
2018
Q2 		$9K Sell
2,100
-5
-0.2% -$23 ﹤0.01% 5849
2018
Q1 		$9K Hold
2,105
– – ﹤0.01% 5742
2017
Q4 		$8K Hold
2,105
– – ﹤0.01% 5932
2017
Q3 		$11K Buy
2,105
+5
+0.2% +$28 ﹤0.01% 6221
2017
Q2 		$13K Sell
2,100
-491
-19% -$2.78K ﹤0.01% 5699
2017
Q1 		$15K Buy
2,591
+2,000
+338% +$11.7K ﹤0.01% 5763
2016
Q4 		$3K Sell
591
-509
-46% -$3.11K ﹤0.01% 6403
2016
Q3 		$8K Hold
1,100
– – ﹤0.01% 5843
2016
Q2 		$10K Sell
1,100
-500
-31% -$4.79K ﹤0.01% 5737
2016
Q1 		$14K Buy
1,600
+100
+7% +$787 ﹤0.01% 5614
2015
Q4 		$14K Buy
1,500
+500
+50% +$6.23K ﹤0.01% 5849
2015
Q3 		$14K Hold
1,000
– – ﹤0.01% 5712
2015
Q2 		$15K Buy
+1,000
New +$16.2K ﹤0.01% 5850
2015
Q1 		– Sell
-2,500
Closed -$37K – 6142
2014
Q4 		$37K Buy
+2,500
New +$39.6K ﹤0.01% 5176
2014
Q2 		– Sell
-1,502
Closed -$33K – 5941
2014
Q1 		$33K Buy
+1,502
New +$15.3K ﹤0.01% 5024

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada's CATX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Perspective Therapeutics (CATX) stake by 24% in Q1 2026, selling an estimated $6.08K and leaving 4,500 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #5914.

Royal Bank of Canada first reported a position in CATX in Q1 2014 and has held it in 46 quarters since. The position peaked at $91K in Q3 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Royal Bank of Canada held 4,500 shares of Perspective Therapeutics worth $19K as of Q1 2026.
  • Royal Bank of Canada sold 1,439 Perspective Therapeutics shares in Q1 2026, an estimated $6.08K.
  • Perspective Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5914 holding.
  • Royal Bank of Canada first reported a position in Perspective Therapeutics in Q1 2014 and has held it in 46 quarters since.
  • Royal Bank of Canada's Perspective Therapeutics position peaked at $91K in Q3 2024.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.